Provided by Tiger Trade Technology Pte. Ltd.

SciSparc Ltd.

4.27
+0.07001.67%
Post-market: 4.270.00000.00%19:15 EDT
Volume:19.50K
Turnover:81.65K
Market Cap:2.45M
PE:0.04
High:4.44
Open:4.25
Low:4.10
Close:4.20
52wk High:80.10
52wk Low:2.98
Shares:573.24K
Float Shares:485.10K
Volume Ratio:3.27
T/O Rate:4.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):98.07
EPS(LYR):-203.8943
ROE:-178.39%
ROA:-41.93%
PB:0.58
PE(LYR):-0.02

Loading ...

SciSparc regains Nasdaq equity compliance, avoids delisting for now

Reuters
·
May 11

Scisparc FY25 net loss widens 94% to USD 12.18 million

Reuters
·
Apr 30

Scisparc Director Alon Dayan Files Initial Beneficial Ownership Statement

Reuters
·
Mar 24

SciSparc Ltd. CEO and CFO Oz Adler Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Scisparc Ltd. Director Moshe Revach Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

SciSparc Ltd. Director Amitay Weiss Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Scisparc Ltd. files Form 3 initial beneficial ownership statement for Director Lior Vider

Reuters
·
Mar 19

BRIEF-Scisparc Neurothera Labs- Clearmind Medicine Collaboration Leads To Patent Application For Depression Therapy

Reuters
·
Mar 16

NeuroThera Labs files Hong Kong patent application for MEAI-PEA depression therapy

Reuters
·
Mar 16

Scisparc: Neurothera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

THOMSON REUTERS
·
Mar 16

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

THOMSON REUTERS
·
Mar 13

BUZZ-U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences

Reuters
·
Mar 12

BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment

Reuters
·
Mar 12

SciSparc-Controlled NeuroThera Labs Publishes PCT Patent for MEAI-PEA Weight Loss and MASLD Therapy

Reuters
·
Mar 12

Scisparc: Neurothera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

THOMSON REUTERS
·
Mar 12

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

TIPRANKS
·
Mar 10

Scisparc Ltd - Neurothera to Buy 56,375 Cliniquantum Shares Representing 54.01% Stake

THOMSON REUTERS
·
Mar 10

Scisparc Ltd - Selling Shareholders May Receive Earn-Out Payments up to $2.5 Mln

THOMSON REUTERS
·
Mar 10

Scisparc: Subsidiary Neurothera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in Cliniquantum, Innovator in Quantum-Based Clinical Trails

THOMSON REUTERS
·
Mar 10

Press Release: SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Dow Jones
·
Mar 10